EffRx Pharmaceuticals has received US Food and Drug Administration (FDA) orphan-drug designation for its proprietary metformin-based product, EX404, for treatment of paediatric polycystic ovary syndrome (PCOS).

Also known as Stein-Leventhal syndrome, PCOS is a heterogeneous disorder of chronic anovulation and hyperandrogenism.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The syndrome is believed to occur due to hormonal imbalance caused by increased levels of androgens and insulin in the body.

EffRx Pharmaceuticals chairman and CEO Christer Rosén said the FDA’s orphan drug designation of EX404 is a significant step forward in the clinical development programme.

“PCOS is a serious problem among women of reproductive age and there is a clear, unmet need for treatments targeting the paediatric and adolescent patient population.”

“PCOS is a serious problem among women of reproductive age and there is a clear, unmet need for treatments targeting the paediatric and adolescent patient population,” Rosén said.

Symptoms of PCOS include menstrual dysfunction, acne, hirsutism, obesity, infertility, insulin resistance and polycystic ovaries by ultrasonography.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Patients suffering with PCOS are at increased risk for type 2 diabetes, metabolic syndrome, infertility, high cholesterol, high blood pressure and heart disease.

Rosén said by diagnosing and treating PCOS earlier in life, young patients can be spared the debilitating physical and emotional symptoms of the condition.

“We look forward to further exploring the potential of EX404 as we build out our clinical development plans for the US and European regulators, which include the expected initiation of our first EX404 clinical trials this fall,” Rosén added. “EX404 is EffRx’s first orphan drug product, and the first product we intend to bring direct to market through an internal sales force.

“As we continue advancing other key strategic initiatives, we plan to further leverage our proprietary effervescent technology to develop other novel therapeutic entities with focus in the orphan drug field.”